In Phase B, the aim is to evaluate the myCare Start service in routine care within the ambulatory primary care medicine and community pharmacy setting in Switzerland. A Type II hybrid effectiveness-implementation study will be conducted to evaluate the effectiveness (improvement in adherence), cost-effectiveness and implementation of the service. This evaluation will allow us to build the necessary contextual relevant evidence base to support sustainable funding of the service in the long term.
Must have mandatory basic health insurance in Switzerland
Must have been newly prescribed one or more new long-term medications in accordance with the following chronic conditions: cadisovascular diseases (incl. hyertension and thromboprophylaxis), diabetes, hyperlipidemia, depression, respiratory illness (asthma and COPD)
Must be able to self-manage treatment (i.e. they live at home without any support to manage their medication, exception: patient uses a pill dispenser and fills it in by him-/herself)
Must be able to understand language spoken by pharmacy staff and can read and understand study documents (French, German, English)
Patients participating or having participated in an education program about their disease or treatment in the last 3 months, led by healthcare providers such as physicians, nurses, pharmacists or other (e.g. education provided by nurses for type I diabetes patients)
Have to be enrolled into the myCare Start service and comply to the requirements of the pharmacy quality system management of having access to a private consultation room or area
Must agree to participate in the research study, including the recruitment of control patients and the delivery of the myCare Start service to intervention patients.
University of Geneva, Switzerland
Lead sponsor
University of Basel
Collaborator
pharmaSuisse
Collaborator
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Collaborator
University of Bern
Collaborator